Medisafe 1 Technologies Announces Three Medical Device Patent Filings

JERUSALEM, June 3, 2011 /PRNewswire-FirstCall/ -- Medisafe 1 Technologies Corp. (OTCBB: MFTH), a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that the company is in the process of submitting three patent applications for medical safety devices.

The first is a computerized locking device that prevents unauthorized medical and drug related products from leaving inventory storage to reduce instances of theft and fraud.

The second is a physical locking device for syringes and capsules that functions differently from the current commercial Medisafe 1 Technologies' product line.

The third is a physical locking device that measures the release of prescribed dosages, to prevent administration of too much medication.

"The filing of these additional patents demonstrates Medisafe 1 Technologies' commitment to research and development, and to finding the best methods to prevent the unauthorized administration of prescription medications," said Jacob Elhadad, CEO of Medisafe 1 Technologies Corp. "We look forward to advancing the products filed from development to commercial phase."

About Medisafe 1 Technologies

Medisafe 1 Technologies seeks to effectively prevent unauthorized administration of a drug or medicinal substance by hypodermic needle. Medisafe's patented technology is a medical assembly with a locking mechanism that is intended to ensure the substance cannot be released from the hypodermic needle without positive pre-matching between the substance and its intended patient.

Forward-Looking Statements

This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Medisafe 1 Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated. Medisafe 1 Technologies Corp. public filings may be viewed at http://www.sec.gov.

    Contact:
    Jacob Elhadad
    CEO
    +972-524440000
    [email protected]

SOURCE Medisafe 1 Technologies Corp.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED